Oncology Institute, Inc. (TOI) Stock Price & Analysis
Oncology Institute, Inc. (TOI) fell 2.17% to USD 4.96 as of June 10, 2026 at 03:30 UTC, according to Nexqual real-time market data.
TOI last closed at USD 5.07; the session ranged USD 4.83–5.15 on volume of 1,726,625 shares. Market capitalization is $495.92M, with a 52-week range of USD 2.02–5.58 (NCM). Source: Nexqual, June 10, 2026 at 03:30 UTC.
Key Statistics (as of June 10, 2026 at 03:30 UTC)
| Price | USD 4.96 |
|---|---|
| Change | ▼ 2.17% (down) |
| Previous Close | USD 5.07 |
| Open | USD 5.06 |
| Day Range | USD 4.83 – 5.15 |
| 52-Week Range | USD 2.02 – 5.58 |
| Volume | 1,726,625 shares |
| Market Cap | $495.92M |
| Exchange | NCM |
Technical Analysis (TOI)
Nexqual's technical model rates TOI "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 03:30 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 66.64 (neutral) |
| vs SMA50 | Above (USD 3.87) |
| MACD | 0.29 (positive) |
Analyst Ratings (TOI)
Wall Street analysts rate TOI "Strong Buy" based on 4 analysts, with a mean price target of USD 7.25 (range USD 5–8), per Nexqual as of June 10, 2026 at 03:30 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 7.25 |
| High Target | USD 8 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (TOI)
| Next Earnings Date | 2026-05-07 |
|---|---|
| Revenue Estimate | $157.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.02 vs est -0.09 ▲ beat |
| 2025-12-31 | USD -0.06 vs est -0.09 ▲ beat |
| 2025-09-30 | USD -0.14 vs est -0.11 ▼ miss |
| 2025-06-30 | USD -0.15 vs est -0.12 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
Financials & Fundamentals (TOI)
| Total Revenue | $545.76M |
|---|---|
| Revenue Growth (YoY) | +41.20% |
| Gross Margin | +15.12% |
| Operating Margin | -4.42% |
| Profit Margin | -7.97% |
| Current Ratio | 1.47 |
| Total Cash | $30.28M |
| Total Debt | $104.91M |
| Free Cash Flow | $-15.31M |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
Financial Health Score (TOI)
Nexqual rates Oncology Institute, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:30 UTC.
| Growth | Strong — Revenue +41% YoY (latest Q) |
|---|---|
| Profitability | Weak — Gross margin 15%, operating -4% |
| Balance Sheet | Mixed — $30M cash vs $105M debt |
| Cash Flow | Weak — FCF negative: -$15M, burning cash |
| Efficiency | Mixed — No data |
Ownership (TOI)
| Insider Ownership | +18.17% |
|---|---|
| Institutional Ownership | +46.05% |
| Shares Outstanding | 99.98M |
| Float | 87.33M |
| Short % of Float | +7.33% |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
Leadership (TOI)
Oncology Institute, Inc. is led by Daniel Virnich FACHE (age 46), CEO & Executive Director, per Nexqual as of June 10, 2026 at 03:30 UTC.
| CEO & Executive Director | Daniel Virnich FACHE (age 46) |
|---|---|
| Chief Financial Officer | Robert Carter (age 39) |
| Senior Vice President of Finance | Stephen Cella |
Major Backers & Investors (TOI)
Notable institutional backers of Oncology Institute, Inc. include Deerfield Management Company, L.P, Kanen Wealth Management LLC, Josh Arnold Investment Consultant, Llc, according to Nexqual as of June 10, 2026 at 03:30 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deerfield Management Company, L.P | 3.36% |
| Kanen Wealth Management LLC | 2.78% |
| Josh Arnold Investment Consultant, Llc | 2.46% |
| Balyasny Asset Management LP | 1.83% |
| Wexford Capital LP | 1.71% |
| CenterBook Partners LP | 1.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.6% |
| BlackRock | 6.9% |
| Geode Capital | 1.76% |
| State Street | 1.46% |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
From Oncology Institute, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Market Overview Our business is focused on caring for adult and senior populations with medical oncology and related care needs, including members of MA plans run by private insurance companies on behalf of the Centers for Medicare and Medicaid Services, or CMS, as well as traditional FFS Medicare, Medicaid, other government healthcare programs and commercial insurance populations.
- Some of the biggest and most respected names in healthcare contract with the TOI PCs to provide oncology care to their members, including Anthem, CareMore Health, Heritage Provider Network and Optum Care.
- In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA, and federal and state consumer protection laws and regulations (e.g., Section 5 of the Federal Trade Commission ("FTC") Act, that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of the TOI PCs.
- We generate these referrals based on the reputation of our doctors and our platform within the communities we serve, as well as our active and direct referrer education efforts.
Partnerships
- In the wake of the Executive Orders and related executive initiatives, a number of pharmaceutical manufacturers have announced new or expanded direct-to-consumer offerings with discounted prices and/or reached agreement with the federal government regarding discounted pricing for drugs, including prices for Medicaid drugs and newly launched products.
- We have entered into a management services agreement with each of the TOI PCs, which are entirely physician owned.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | USD 7.9 | ▲ 2.6% |
| BBLG | Bone Biologics Corp | USD 1.23 | ▼ 1.52% |
| ICU | SeaStar Medical Holding Corpora | USD 2.78 | ▼ 5.44% |
| LIXT | Lixte Biotechnology Holdings, I | USD 6.87 | ▼ 1.86% |
| SABS | SAB Biotherapeutics, Inc. | USD 3.36 | ▼ 0.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:30 UTC. This page is informational and not investment advice.